Milestone Pharmaceuticals Inc (MIST) has a current Price-to-Book (P/B) ratio of 10.16. Compared to its 3-year average P/B ratio of 2.27, the current P/B ratio is approximately 347.13% higher. Relative to its 5-year average P/B ratio of 2.33, the current P/B ratio is about 336.08% higher. Milestone Pharmaceuticals Inc (MIST) has a Forward Free Cash Flow (FCF) yield of approximately -20.72%. Compared to its 3-year average FCF yield of -35.33%, the current FCF yield is approximately -41.35% lower. Relative to its 5-year average FCF yield of -27.90%, the current FCF yield is about -25.74% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MIST competitors is 7732.79, providing a benchmark for relative valuation. Milestone Pharmaceuticals Inc Corp (MIST.O) exhibits a P/S ratio of 5.09, which is -99.93% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MIST increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MIST in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MIST currently overvalued or undervalued?

What is Milestone Pharmaceuticals Inc (MIST) fair value?

MIST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Milestone Pharmaceuticals Inc (MIST) is between to according to relative valuation method.

How does MIST's valuation metrics compare to the industry average?

The average P/S ratio for MIST's competitors is 7732.79, providing a benchmark for relative valuation. Milestone Pharmaceuticals Inc Corp (MIST) exhibits a P/S ratio of 5.09, which is -99.93% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Milestone Pharmaceuticals Inc (MIST) as of Mar 03 2026?

As of Mar 03 2026, Milestone Pharmaceuticals Inc (MIST) has a P/B ratio of 10.16. This indicates that the market values MIST at 10.16 times its book value.

What is the current FCF Yield for Milestone Pharmaceuticals Inc (MIST) as of Mar 03 2026?

As of Mar 03 2026, Milestone Pharmaceuticals Inc (MIST) has a FCF Yield of -20.72%. This means that for every dollar of Milestone Pharmaceuticals Inc's market capitalization, the company generates -20.72 cents in free cash flow.

What is the current Forward P/E ratio for Milestone Pharmaceuticals Inc (MIST) as of Mar 03 2026?

As of Mar 03 2026, Milestone Pharmaceuticals Inc (MIST) has a Forward P/E ratio of -4.21. This means the market is willing to pay $-4.21 for every dollar of Milestone Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Milestone Pharmaceuticals Inc (MIST) as of Mar 03 2026?

As of Mar 03 2026, Milestone Pharmaceuticals Inc (MIST) has a Forward P/S ratio of 5.09. This means the market is valuing MIST at $5.09 for every dollar of expected revenue over the next 12 months.

MIST Valuation